Drug Database
T-

T-Bactum (EB23 18235Y / EB2318235Y)

✓ Approved

Essex Bio-Technology Limited · therapeutic agent

What is T-Bactum?

T-Bactum is a therapeutic agent developed by Essex Bio-Technology Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesEB23 18235Y, EB2318235Y
CompanyEssex Bio-Technology Limited
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Essex Bio-Technology Limited

Therapeutic Indications

T-Bactum is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsOral infection✓ Approved

Related Research Articles

PubMediScience2026-08-30

Single-cell transcriptomic signatures of T cells associated with rituximab responsiveness in idiopathic nephrotic syndrome.

Koshi-Ito Eri E, Watanabe Yu Y, Onogi Chikao C, Horinouchi Asuka A et al.

Rituximab (RTX) is increasingly used in steroid-dependent minimal change disease, a leading cause of idiopathic nephrotic syndrome (INS), yet predictors of response remain unclear. Although RTX primarily targets B cells, T cells are also implicated in INS pathogenesis. We investigated RTX-induced T cell dynamics by single-cell RNA sequencing/T cell receptor profiling of peripheral T cells from three responders and three non-responders before and after RTX treatment. Responders exhibited RTX-driven broad transcriptomic remodeling, accompanied by reduced exhausted CD8+ T cells and clonal expansion of CD4+ cytotoxic T cells with enhanced oxidative phosphorylation (OXPHOS) signatures, whereas non-responders showed marginal changes. In a separate cohort, reactive oxygen species (ROS) levels tended to be higher in responders, and declined post-RTX, collectively associating enhanced mitochondrial activity with favorable response. Reanalysis of childhood INS data supported altered B-T cell crosstalk and T cell metabolism. Together, T cells may influence RTX responsiveness, warranting further biomarker studies.

PMID 42668630
Read full article →
PubMedActa tropica2026-08-30

Dengue virus rNS3pro immunization is associated with the expansion of regulatory-like T-cell phenotypes in BALB/c mice.

Romero-Cruz Víctor Adolfo VA, Ramos-Ligonio Angel A, Murrieta-León Diana Lizzet DL, Placier-Sosa Denisse D et al.

Dengue virus (DENV) nonstructural protein 3 (NS3) is essential for viral replication and host immune evasion. While its protease domain (NS3pro) has been linked to T-cell anergy, its role in inducing regulatory T cells (Tregs) requires further exploration. To analyze the induction of diverse regulatory T-cell populations in BALB/c mice immunized with recombinant rNS3pro proteins from the four DENV serotypes. Mice were immunized with rNS3pro, and splenocytes were stimulated in vitro with homologous proteins. Cytokine expression and T-cell phenotypes-including markers for activation, exhaustion, and cytotoxicity-were analyzed via RT-PCR, ELISA, and flow cytometry. rNS3pro immunization induced a predominantly regulatory-associated response characterized by significant IL-10 expression. A marked expansion of CD4+CD25+ T cells (23.5% vs. 1.05% in controls) was observed, encompassing CD25+FoxP3+ regulatory-like T cells, alongside FoxP3-independent subsets expressing CD25+IL-10+ and CD25+TGF-β+. These cells co-expressed cytotoxicity-associated (FoxP3+Perforin+/GzB+) and co-inhibitory (CTLA-4+, PD-1+) markers. Effector CD8+ T-cell proliferation was significantly inhibited and could not be restored by exogenous IL-2. In conclusion, DENV rNS3pro immunization drives a robust expansion of multifaceted regulatory-like T-cell phenotypes. This immunomodulatory response correlates with compromised CD8+ effector proliferation, identifying the NS3 protease domain as a potential player in DENV immune evasion strategies.

PMID 42669351
Read full article →
PubMediScience2026-08-30

Uridine and pyruvate supplementation is associated with Th1 polarization during mitotoxic antibiotic therapy.

De Santis Stefania S, Rutigliano Monica M, Simone Federica F, Larocca Letizia L et al.

Antibiotics with off-target mitochondrial toxicity can impair host immunity, yet their impact on human adaptive immunity in vivo remains unclear. Because T cell activation and differentiation depend on mitochondrial metabolism, antibiotic-induced mitochondrial stress may alter T helper cell function. We investigated whether uridine and pyruvate (UP) supplementation modulates immune responses in patients receiving mitotoxic antibiotics. In a pilot observational study, 67 patients undergoing prophylactic antibiotic therapy received either antibiotics alone or antibiotics plus daily UP supplementation. Antibiotic exposure increased circulating growth differentiation factor-15 (GDF15), indicating mitochondrial stress, and altered T cell response. UP supplementation was associated with immune features consistent with preserved inflammatory competence, including a trend toward Th1 polarization. These findings suggest that mitotoxic antibiotics can influence human T cell programs and support the hypothesis that UP supplementation may preserve pro-inflammatory T cell responses during antibiotic therapy, representing a potential metabolic strategy to mitigate antibiotic-induced immunotoxicity.

PMID 42668664
Read full article →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

Kawamoto Hiroshi H, Kawase Takakazu T, Nagano Seiji S

Cancer immunotherapy using patient-derived T cells genetically modified in vitro has been demonstrated to be effective. However, issues such as cost, time, and unstable quality must be resolved. To overcome these barriers, we developed the TCR-PS cell method, in which a specific TCR gene is introduced into pluripotent stem cells (PS cells), such as ES cells or iPS cells, and T cells are generated from those PS cells. We are currently preparing for a clinical trial in acute myeloid leukemia, targeting the WT1 antigen, with iPS cells provided by the CiRA Foundation as the starting material. In parallel, we are also investigating this approach for viral infections and preparing for clinical trials in COVID-19, with HLA-deficient ES cells as the starting material. This method should enable stockpiling of T cell therapies against known viruses such as SARS or avian influenza. Even for outbreaks caused by unknown viruses, it should be possible to produce T cell therapies within 100 days after the virus genome is defined.

PMID 42669514
Read full article →
PubMedCryobiology2026-08-30

Development of techniques for cryopreserving giant clam larvae.

Castillo Raul Emid RE, Tsai Sujune S, Chen Bonien B, Wen Zhi-Hong ZH et al.

Giant clams (Tridacna spp.) are keystone reef organisms that play important ecological roles in Indo-Pacific coral reef ecosystems. However, their populations have declined substantially because of overexploitation, habitat degradation, and climate change. Cryopreservation offers a potential strategy for preserving genetic resources and supporting future conservation and restoration efforts. In this study, we evaluated the feasibility of cryopreserving D-stage larvae of Tridacna crocea and T. maxima using a two-step freezing protocol. The effects of different cryoprotectants, concentrations, and equilibration times on post-thaw larval integrity and motility were assessed. Larval development was monitored using microscale culture techniques and microscopic observations. The results demonstrated species-specific responses to cryopreservation treatments, with T. maxima generally exhibiting greater cryotolerance than T. crocea. Ethylene glycol produced the highest larval integrity percentage (LIP) in both species. In addition, glycerol and propylene glycol yielded relatively high LIP values in T. crocea, whereas methanol and dimethyl sulfoxide (DMSO) performed more effectively in T. maxima. Post-thaw motility was observed only in a limited number of treatment groups, with the highest motility recorded in larvae treated with 0.75 M glycerol for 30 min and 0.5 M DMSO for 20 min. In contrast, non-cryopreserved control larvae exhibited a progressive decline in motility during culture, decreasing to 12.1% in T. maxima and 4.0% in T. crocea after 24 h. To our knowledge, this study represents the first investigation of cryopreservation in tridacnid D-stage larvae. Although post-thaw motility remained limited, the successful preservation of larval structural integrity demonstrates the potential of cryopreservation as a conservation tool for giant clams. Further optimization of species-specific cryopreservation protocols will be necessary to improve post-thaw recovery and support long-term genetic resource banking.

PMID 42669249
Read full article →
PubMedMycoKeys2026-08-30

Molecular phylogeny and morphology reveal three new species and two new records of Trichoderma (Hypocreaceae, Hypocreales) from China.

Lou Fang-Wei FW, Chen Bao-Zheng BZ, Tan Li-Man LM, Xiao Jia-Chen JC et al.

Species of Trichoderma are globally distributed across diverse ecosystems. In this study, four Trichoderma strains were isolated from Ophiocordyceps jinguangensis, two from O. sinensis, and two from Dracaena sp. To determine their taxonomic placement, maximum likelihood and Bayesian inference analyses of ITS, tef1-α, and rpb2 sequences, along with morphological examinations, were conducted. Integrating phylogenetic and morphological evidence, these strains were identified as three new species, Trichoderma diqingense, T. dracaenae, and T. yuxiense, which are distributed in three distinct clades of Trichoderma (i.e., Harzianum, Viride, and Polysporum, respectively), and two known species, T. fertile and T. paraviridescens, which are newly recorded from the substrate O. sinensis. Descriptions and illustrations of all species are provided. These findings expand the understanding of Trichoderma species and substrate diversity, providing a taxonomic basis for future studies.

PMID 42668876
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about T-Bactum